India’s second largest drug maker by domestic sales, Cipla has reported a jump of 17.44% in its standalone net profit at Rs 308.97 crore for the second quarter ended September 30, 2011 on increased sales and cost savings. The company had posted a net profit of Rs 263.08 crore in the July-September quarter of the previous fiscal.
Total income of the company also rose by 9.16% to Rs 1802.33 crore during the reporting quarter from Rs 1651.03 crore in the year-ago period.
Exports to Africa were up 41% and the firm benefited from operational efficiencies in material consumption and product mix. Cipla’s sales in the domestic market grew on expected lines by 12%. Sales in Middle East were affected by changed market circumstances.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: